0837 GMT - GSK needs to convince investors of a sustainable vaccine outlook after it cut the 2025 sales target of its jabs, Shore Capital analyst Sean Conroy says. The British pharma company now guides for a low single-digit decrease in vaccine sales for this year after a slowdown in the U.S., notably for its RSV shot Arexvy that missed consensus estimates by 18%, the analyst says. "Some tangible evidence the transient challenges facing Shingrix [shingles vaccine] and Arexvy can be navigated will likely be needed to reinstill the conviction in management's longer-term expectations for these," he says in a note. Shares are up 5.7% at 1,458.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。